HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

SYN-004

an orally administered, modified version of P1A beta-lactamase for protecting gut bacteria from antibiotics

Networked: 6 relevant articles (0 outcomes, 3 trials/studies)

Bio-Agent Context: Research Results

Enzymes and Coenzymes: 1
- Enzymes: 152586
  - Hydrolases: 2166
    - Amidohydrolases: 43
      - beta-Lactamases: 2628
        SYN-004: 6
Amino Acids, Peptides, and Proteins: 1
- Proteins: 484843
  - Recombinant Proteins: 2754
    - SYN-004: 6

Experts

1.	Hubert, Steven: 3 articles (12/2017 - 09/2016)
2.	Connelly, Sheila: 2 articles (01/2019 - 10/2016)
3.	Kaleko, Michael: 2 articles (01/2019 - 10/2016)
4.	Parsley, Todd: 2 articles (01/2019 - 10/2016)
5.	Kokai-Kun, John F: 2 articles (10/2018 - 09/2016)
6.	Bristol, J Andrew: 2 articles (10/2016 - 09/2016)
7.	Sliman, Joseph: 2 articles (10/2016 - 09/2016)
8.	Ge, Hui: 1 article (01/2019)
9.	Carman, Robert J: 1 article (10/2018)
10.	Sarver, J Lauren: 1 article (10/2018)

Related Diseases

1.	Diarrhea 10/01/2016 - "Phase 2 studies are in progress to assess the utility of SYN-004 for the prevention of antibiotic-associated diarrhea and Clostridium difficile disease." 09/01/2016 - "Tolerability and Pharmacokinetics of SYN-004, an Orally Administered β-Lactamase for the Prevention of Clostridium difficile-Associated Disease and Antibiotic-Associated Diarrhea, in Two Phase 1 Studies."
2.	Clostridium Infections 10/01/2018 - "During a Phase 2b study with SYN-004 (ribaxamase) for prevention of Clostridium difficile infection (CDI) conducted in North America and Eastern Europe, 45 C. " 10/01/2016 - "Development of SYN-004, an oral beta-lactamase treatment to protect the gut microbiome from antibiotic-mediated damage and prevent Clostridium difficile infection."
3.	Dysbiosis 12/20/2017 - "Formulation development of SYN-004 (ribaxamase) oral solid dosage form, a β-lactamase to prevent intravenous antibiotic-associated dysbiosis of the colon." 07/01/2017 - "SYN-004 (ribaxamase), an oral beta-lactamase, mitigates antibiotic-mediated dysbiosis in a porcine gut microbiome model." 01/16/2019 - "Proof of concept for this approach was achieved with an orally-administered beta-lactamase enzyme, SYN-004 (ribaxamase), that was demonstrated to degrade ceftriaxone excreted into the GI tract and protect the gut microbiome from antibiotic-mediated dysbiosis. " 12/20/2017 - "SYN-004 (ribaxamase) delayed release drug product is a multi-particulate, hard capsule for oral delivery of a recombinant β-lactamase enzyme designed to degrade β-lactam antibiotics administered intravenously, and thus prevent colon dysbiosis. "
4.	Infections 10/01/2018 - "Characterization of Clostridium difficile isolates collected during a phase 2b clinical study with SYN-004 (ribaxamase) for the prevention of C. difficile infection."

Related Drugs and Biologics

1.	Anti-Bacterial Agents (Antibiotics)
2.	beta-Lactamases (beta-Lactamase)
3.	Enzymes
4.	Lactams
5.	Dosage Forms (Dosage Form)
6.	Ceftriaxone (Ceftriaxon)
7.	Capsules (Microcapsules)